Vertex Pharmaceuticals Outperforms Market with 0.46% Gains: Here’s What You Need to Know
June 16, 2023
☀️Trending News
Vertex ($NASDAQ:VERX) Pharmaceuticals rose above the Stock Market with their closing price of $334.11, representing an increase of +0.46% compared to the previous trading day. This positive market performance is especially noteworthy given the recent volatility in the markets due to the pandemic. For those unfamiliar with Vertex Pharmaceuticals, it is a biotechnology company based in the United States which focuses on the development and commercialization of small molecule drugs for serious diseases and medical conditions. Over the past two decades, Vertex has become one of the leading players in the global biotechnology industry, pioneering novel therapies to treat cystic fibrosis, cancer, and other serious diseases.
While the future of the markets remain uncertain, Vertex Pharmaceuticals appears to be well-positioned to weather any potential economic downturns. Investors should remain vigilant to any potential headwinds that may affect Vertex’s stock price in the coming months.
Analysis
GoodWhale has analyzed VERTEX and its financials. According to our Star Chart, VERTEX is strong in growth, medium in profitability, and weak in assets and dividend. Based on this rating, we classify VERTEX as a ‘cheetah’, which is a type of company that has achieved high revenue or earnings growth but is considered less stable due to lower profitability. Investors interested in such companies may include those looking for higher growth potential with a greater risk appetite. Despite its weakened assets and dividend, VERTEX has a high health score of 8/10 with regard to its cashflows and debt, meaning that it is capable to sustain future operations in times of crisis. As VERTEX is a high risk-high reward option, those with greater risk tolerance may be more likely to invest in the company. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Vertex. More…
| Total Revenues | Net Income | Net Margin |
| 509.39 | -30.1 | -5.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Vertex. More…
| Operations | Investing | Financing |
| 81.01 | -85.35 | -24.22 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Vertex. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 725.52 | 502.04 | 1.48 |
Key Ratios Snapshot
Some of the financial key ratios for Vertex are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 14.9% | – | -3.4% |
| FCF Margin | ROE | ROA |
| 1.4% | -4.8% | -1.5% |
Peers
The company was founded in 1978 and is headquartered in Berwyn, Pennsylvania. Vertex Inc has several competitors, including KLDiscovery Inc, TKC Corp, and Business-intelligence of Oriental Nations Corp Ltd.
– KLDiscovery Inc ($OTCPK:KLDI)
KLDiscovery Inc is a global provider of electronic discovery, data recovery, and litigation support services. The company has a market cap of 106.98M as of 2022 and a Return on Equity of -7.61%. KLDiscovery Inc provides services to law firms, corporations, and government agencies worldwide. The company offers a full range of services, from data collection and processing to document review and trial preparation.
– TKC Corp ($TSE:9746)
TKC Corp is a publicly traded company with a market cap of 199.69B as of 2022. The company has a Return on Equity of 9.32%. TKC Corp is a diversified conglomerate with businesses in a variety of industries including construction, real estate, hospitality, and health care. The company has a strong presence in the United States, Asia, and Europe.
– Business-intelligence of Oriental Nations Corp Ltd ($SZSE:300166)
Oriental Nations Corp Ltd is a 9.89B market cap company with a ROE of 1.79%. The company is involved in the business of intelligence and information technology.
Summary
Vertex Pharmaceuticals has outperformed the stock market by a wide margin, closing at $334.11 on the most recent trading day. This equates to a 0.46% increase from the previous session, indicating that the company’s stock is performing well and has potential to continue to rise. Investors may want to take a closer look at Vertex Pharmaceuticals for investing opportunities, since it has been able to outshine the stock market as a whole. It is important to do your own research and analyze the company’s financials before investing in Vertex Pharmaceuticals.
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
